Paperwork Before the Inspector Calls: Separating a Research Peptide from a Licensed Medicine
External quality-system inspections rarely unravel at the bench. They unravel in the folder where a laboratory keeps purchase records, batch certificates and product labels for the materials it handles. When an assessor asks how a lyophilised research peptide was sourced, stored and documented, the answer must make one thing unmistakable: this was research-use-only material, not a licensed medicine. That distinction is an administrative discipline, and it is far easier to build before the inspection window opens than during it.
The Legal and Documentary Boundary Between a Research Peptide and a Licensed Medicine
An inspector reviewing a laboratory’s quality system will want to see that the materials on site are what the paperwork says they are. For a licensed medicine, that paper trail is prescribed: a marketing authorisation, a summary of product characteristics, a patient information leaflet, named indications, dose regimens and batch certification against pharmacopoeial requirements. A research peptide sits on the other side of that boundary entirely. Research Sciences states plainly that its products are not medicines, medical devices, injectables, treatments or food supplements under UK law, and that they are not supplied for therapeutic, clinical or diagnostic purposes. Nothing in a research-use-only file should read like documentation for a licensed product, and nothing in a licensed-medicine file should be improvised for research stock.
The documentary signal an assessor typically looks for first is the label. The shop’s FAQs describe products as labelled “For Research Use Only – Not for Human Consumption”, a position the company describes as being in line with MHRA guidance. That is the supplier’s stated position, not legal advice for any individual laboratory, and it should be read alongside the purchaser’s own obligations: lawful use, safe handling, storage, disposal, COSHH compliance and a documented judgement that the material suits the intended in-vitro application. If a file contains a patient leaflet, a dosing schedule or a therapeutic claim, the inspector is entitled to ask why. If it contains a CoA, an RUO label, a COSHH assessment and a storage record, the story is coherent from the outset. Materials supplied are not for human or veterinary use, and the paperwork should say so repeatedly and unambiguously.
It also helps to record what the supplier will not do. Research Sciences states that it does not provide therapeutic, medical, performance, injection, ingestion or dosing guidance, and that orders inconsistent with its compliance standards may be refused. That refusal pathway belongs in the inspection narrative too: procurement records showing that an enquiry was queried or declined demonstrate a control, not an inconvenience. Equally, a laboratory should be able to show that it never sought such guidance in the first place, because the intended use was analytical rather than clinical.
Reading the Documentation Stack: Labels, Certificates and Test References
Vial labels and reference codes
Once the category is unambiguous, the second line of questioning is whether the documents attach to the right vial. The shop’s label reference format combines a SKU code and an expiry date, for example BPC10-03/27, and links to the corresponding CoA. Researchers should quote that reference when contacting the shop about documentation, and should keep a copy of the label in the file rather than relying on the order confirmation alone. For teams sourcing research materials through a UK supplier such as Peptide uk, the inspector’s first question is rarely whether a certificate exists; it is whether the certificate matches the vial in front of them.
What the CoA should and should not be asked to prove
The FAQs state that every product includes a CoA covering purity and identity by HPLC, and the About page describes full-spectrum testing across purity, identity, heavy metals and endotoxin evaluation of submitted samples. The homepage lists “CoAs Janoshik Analytical Reports”, and site guidance discusses heavy-metal (ICP-MS) and endotoxin testing. Published headline lines such as “≥99% Verified Purity” and “UK Research Materials Over 99.1% Purity” are the shop’s current published wording at the time of writing and should be reconfirmed against the live site and, more importantly, against the batch CoA — the FAQs note that exact purity is stated on that document. A CoA is evidence about a batch; it is not a licence, a clinical opinion or a substitute for the laboratory’s own suitability assessment.
Internal Test References and restocked stock
Restocked products may carry the same Internal Test Reference as earlier stock. An ITR links to associated sample testing reports; it does not confirm that separate deliveries come from the same production lot or that they have been independently tested separately. Inspection files should describe an ITR as a document link and nothing more. Vial cap colours and other packaging may vary between deliveries, and cap colour is not an indicator of identity, analytical quality or manufacturing origin. Where an assessor queries an apparent mismatch between two deliveries, the answer lies in the batch documentation, not in the appearance of the closure.
A Pre-Inspection Checklist: Turning Research-Use-Only Claims into an Auditable File
Separate the two document sets
Keep research-use-only material records in their own indexed section, physically or digitally apart from any licensed medicine or clinical consumable documentation held by the same organisation. Each entry should carry the catalogue name, the label reference, the CoA, the storage location and the named person responsible. Where a peptide is presented as a lyophilised powder, that form should be recorded as supplied, alongside any excipient declared by the supplier — the FAQs note that all peptides contain trace amounts of mannitol — and a note that no blended peptides are supplied, so any combined-use experimental design is a documented laboratory decision rather than a product characteristic.
Record handling and storage as a workflow
Storage entries should reflect the published handling guidance: lyophilised material at −20°C or below, sealed with desiccant and protected from moisture, heat and light, with repeated freeze–thaw cycles avoided, vials allowed to reach room temperature before opening, and only the amount required for the experiment removed. Reconstituted material is less stable and should be held at 2–8°C for short-term laboratory use. Reconstitution records stay inside the in-vitro workflow — diluent volume, target concentration for the assay, date and operator — and the shop’s free reconstitution calculator is for laboratory research use only and must never be used for human or veterinary dosing.
Align fulfilment and payment records
Fulfilment evidence should be consistent with the published terms at the time of order: all orders dispatched the next working day, shipped via Royal Mail Tracked 24 with a tracking number after dispatch, delivery times described as estimates that may vary in peak periods, and the homepage “24hr UK Delivery” line treated as marketing wording rather than a guarantee. No returns are accepted once dispatched, with refunds only for damage, incorrect supply or quality issues under the Refunds & Returns Policy. Payment records should show Pay-By-Bank or Open Banking through providers such as Wallid, described as FCA-regulated, with no card payments accepted and no bank login details stored. Where an inspector challenges any of these points, the live site wording and the batch CoA should be reconfirmed and attached to the file as the definitive reference.
Windhoek social entrepreneur nomadding through Seoul. Clara unpacks micro-financing apps, K-beauty supply chains, and Namibian desert mythology. Evenings find her practicing taekwondo forms and live-streaming desert-rock playlists to friends back home.
